Inovio Pharmaceuticals, Inc.

$1.25+2.05%(+$0.03)
TickerSpark Score
40/100
Weak
40
Valuation
20
Profitability
55
Growth
56
Health
30
Momentum

Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a INO research report →

52-Week Range11% of range
Low $1.03
Current $1.25
High $2.98

Companywww.inovio.com

Inovio Pharmaceuticals, Inc. , a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids.

CEO
Jacqueline E. Shea
IPO
1998
Employees
134
HQ
Plymouth Meeting, PA, US

Price Chart

-41.55% · this period
$2.87$1.96$1.05May 20Nov 18May 20

Valuation

Market Cap
$66.72M
P/E
-10.13
P/S
0.00
P/B
141.78
EV/EBITDA
-0.58
Div Yield
0.00%

Profitability

Gross Margin
0.00%
Op Margin
0.00%
Net Margin
0.00%
ROE
-666.47%
ROIC
-567.11%

Growth & Income

Revenue
$65.34K · -69.99%
Net Income
$-84,945,901 · 20.80%
EPS
$-1.81 · 54.18%
Op Income
$-86,822,104
FCF YoY
14.97%

Performance & Tape

52W High
$2.98
52W Low
$1.03
50D MA
$1.35
200D MA
$1.86
Beta
1.44
Avg Volume
2.50M

Get TickerSpark's AI analysis on INO

Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.

Get Pro Access →

30-day money-back guarantee · cancel anytime

Recent Insider Transactions

DateInsiderTypeShares
May 15, 26Shea Jacqueline Elizabethother17,744
May 15, 26Shea Jacqueline Elizabethother7,717
May 15, 26Shea Jacqueline Elizabethother17,744
May 15, 26KIES PETERother4,771
May 15, 26KIES PETERother2,571
May 15, 26KIES PETERother4,771
May 15, 26Humeau Laurentother4,771
May 15, 26Humeau Laurentother1,712
May 15, 26Humeau Laurentother4,771
May 15, 26Sumner Michael Johnother2,385

Our INO Coverage

We haven't published any research on INO yet

For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.

Generate INO Report →

Similar Companies